Benjamin R. Roman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Benjamin R. Roman has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Ian Ganly
Department of Head and Neck Surgery Memorial Sloan Kettering Cancer Center New York New York
4 shared publications- Marc A. Cohen
Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA
4 shared publications Piyush Gupta
Department of Otolaryngology University of Missouri Columbia Missouri USA
4 shared publicationsShivangi Lohia
Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York
4 shared publicationsSnehal G. Patel
Memorial Sloan Kettering Cancer Center, New York, New York
4 shared publications- Allison Lipitz-Snyderman
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
3 shared publications
Latest Publications
- 9 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500510
Feasibility Study: Early Experiences With a Cancer Center's Virtual Expert Medical Opinion Program
PURPOSE: Second opinion consultations are a promising strategy to identify errors in diagnosis and recommend optimal treatment. Yet, there are geographic barriers. By bringing high-level care to patients where they live, virtual second opinion programs might benefit populations without access to specialty cancer centers. We conducted a feasibility study that examined changes in treatment recommended through a national virtual second opinion program based at a comprehensive cancer center. METHODS: Memorial Sloan Kettering Cancer Center (MSK)'s virtual second opinion program was developed via a national cancer employer benefits solution. Each review was conducted by an MSK subspecialist and supported by a digital platform. After conducting the second opinion, subspecialists answered a questionnaire regarding their perceptions of the expected impact of recommended treatment changes. Here, we report findings from December 2023 to November 2024. RESULTS: There were 231 cases completed. There were 55% women, with a median age of 56 years. Patients resided across the United States, with 56% from the South. The most common cancer categories were breast, GI and mixed tumor (GMT), and prostate. Cases were reviewed by 76 unique subspecialists. Subspecialists perceived that they made a meaningful change in recommended treatment (expected to affect patient outcomes) in 75 cases (32%). Expected changes included better prognosis/survival (n = 49, 65%), improved short-term morbidity/quality of life/toxicity (n = 36, 48%), or improved long-term morbidity/quality of life/toxicity (n = 49, 65%). There was a higher percent of recommended changes for liquid compared with solid tumor cases (liquid: 15 of 31, 48%; solid: 60 of 200, 30%). CONCLUSION: Findings are helpful for understanding the potential impact of a virtual second opinion program for patients with cancer and for developing strategies to reach underserved communities with geographic access barriers to high-quality cancer care from subspecialists.
- 9 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500510
Feasibility Study: Early Experiences With a Cancer Center's Virtual Expert Medical Opinion Program
PURPOSE: Second opinion consultations are a promising strategy to identify errors in diagnosis and recommend optimal treatment. Yet, there are geographic barriers. By bringing high-level care to patients where they live, virtual second opinion programs might benefit populations without access to specialty cancer centers. We conducted a feasibility study that examined changes in treatment recommended through a national virtual second opinion program based at a comprehensive cancer center. METHODS: Memorial Sloan Kettering Cancer Center (MSK)'s virtual second opinion program was developed via a national cancer employer benefits solution. Each review was conducted by an MSK subspecialist and supported by a digital platform. After conducting the second opinion, subspecialists answered a questionnaire regarding their perceptions of the expected impact of recommended treatment changes. Here, we report findings from December 2023 to November 2024. RESULTS: There were 231 cases completed. There were 55% women, with a median age of 56 years. Patients resided across the United States, with 56% from the South. The most common cancer categories were breast, GI and mixed tumor (GMT), and prostate. Cases were reviewed by 76 unique subspecialists. Subspecialists perceived that they made a meaningful change in recommended treatment (expected to affect patient outcomes) in 75 cases (32%). Expected changes included better prognosis/survival (n = 49, 65%), improved short-term morbidity/quality of life/toxicity (n = 36, 48%), or improved long-term morbidity/quality of life/toxicity (n = 49, 65%). There was a higher percent of recommended changes for liquid compared with solid tumor cases (liquid: 15 of 31, 48%; solid: 60 of 200, 30%). CONCLUSION: Findings are helpful for understanding the potential impact of a virtual second opinion program for patients with cancer and for developing strategies to reach underserved communities with geographic access barriers to high-quality cancer care from subspecialists.
- Top Cited Papers
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (3) , 357-361
Liability Risks of Ambient Clinical Workflows With Artificial Intelligence for Clinicians, Hospitals, and Manufacturers
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (3) , 357-361
Top Cited PapersLiability Risks of Ambient Clinical Workflows With Artificial Intelligence for Clinicians, Hospitals, and Manufacturers
- 2 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (10) , 1872-1879
What Is the Cost Impact of Second Opinions in Oncology? A Retrospective Review
PURPOSE: Second opinions in oncology may optimize treatment plans, resulting in improved outcomes such as prognosis and morbidity. Changes in treatment plans are often de-escalations in treatment intensity. However, data on the cost impact of changes in cancer treatment resulting from second opinions are limited. METHODS: We used a cohort of 120 patients who presented to a high-volume cancer center for a second opinion and also had a documented first opinion—30 patients each from four disease types: colorectal, head and neck, lung, and myeloma. For the 43 total patients who had a change in treatment from the second opinion compared with the first opinion, we estimated costs of treatment for the first and second opinions across the modalities of surgery, radiation, and drug treatment. RESULTS: Among the 43 patients with a change between the first and second opinions, seven patients had a higher cost from the second opinion, 31 had a lower cost, and five had the same cost. Averaged across all 120 cases—43 with changes in treatment and the rest without—mean cost savings were $15,015 in US dollars (USD) per patient, ranging by disease type from $2,517 USD (lung) to $43,437 USD (myeloma). Decreases in cost were due to less-intensive surgery or drug therapy regimens, or shifts from treatment to no treatment (observation). CONCLUSION: Further investigation is needed across cancer types and in other settings to confirm the finding of de-escalations and resulting cost savings from second opinions.
- 2 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (10) , 1872-1879
What Is the Cost Impact of Second Opinions in Oncology? A Retrospective Review
PURPOSE: Second opinions in oncology may optimize treatment plans, resulting in improved outcomes such as prognosis and morbidity. Changes in treatment plans are often de-escalations in treatment intensity. However, data on the cost impact of changes in cancer treatment resulting from second opinions are limited. METHODS: We used a cohort of 120 patients who presented to a high-volume cancer center for a second opinion and also had a documented first opinion—30 patients each from four disease types: colorectal, head and neck, lung, and myeloma. For the 43 total patients who had a change in treatment from the second opinion compared with the first opinion, we estimated costs of treatment for the first and second opinions across the modalities of surgery, radiation, and drug treatment. RESULTS: Among the 43 patients with a change between the first and second opinions, seven patients had a higher cost from the second opinion, 31 had a lower cost, and five had the same cost. Averaged across all 120 cases—43 with changes in treatment and the rest without—mean cost savings were $15,015 in US dollars (USD) per patient, ranging by disease type from $2,517 USD (lung) to $43,437 USD (myeloma). Decreases in cost were due to less-intensive surgery or drug therapy regimens, or shifts from treatment to no treatment (observation). CONCLUSION: Further investigation is needed across cancer types and in other settings to confirm the finding of de-escalations and resulting cost savings from second opinions.
- Open Access
- 18 February 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (5) , 1560-1569
Communication of Voice‐Related Complications in Thyroidectomy: A Qualitative Analysis
Objective: This study aims to characterize patient–surgeon discussions of voice‐related complications during thyroidectomy for low‐risk thyroid cancer.Study Design: A qualitative study.Setting: Three academic medical centers.Methods: Pre‐operative clinic visits between 14 surgeons (6 otolaryngologists and 8 endocrine surgeons) and 49 patients with low‐risk (cT1‐2, N0) thyroid cancer were audio‐recorded and transcribed. Qualitative analysis was used to evaluate surgeon counseling strategies and patient concerns related to voice.Results: Patients aged from 20 to 77 years old were predominantly female (77.6%) and white (89.9%). Surgeons presented risk with negative framing and numerical percentages (1%‐4%) and/or qualified the risk as “low” or “small” for a lobectomy, but a “much bigger deal” for bilateral nerve injury in total thyroidectomy. At a minimum, surgeons referred to voice dysfunction as “voice change.” Some further described “hoarseness” or the “inability to project voice.” Other surgeons imitated what voice dysfunction would sound like. A few surgeons probed the importance of voice to a patient's life. One surgeon imparted that having a voice‐related complication “can be really emotional.” Patients responded with varying degrees of concern about voice changes after surgery, from feeling “super concerned … about losing [their] voice” to feeling “ok” with it “as long as [they're] around to deal with it.”Conclusion: Significant variability exists in how surgeons describe and set expectations about voice‐related complications. The degree to which patients value voice‐related outcomes differed based on their occupation and hobbies, but this was tempered by their cancer diagnosis. Further research is needed to identify optimal disclosure of voice‐related risks and expectations.
- 18 February 2025
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 172 (5) , 1560-1569
Open AccessCommunication of Voice‐Related Complications in Thyroidectomy: A Qualitative Analysis
Objective: This study aims to characterize patient–surgeon discussions of voice‐related complications during thyroidectomy for low‐risk thyroid cancer.Study Design: A qualitative study.Setting: Three academic medical centers.Methods: Pre‐operative clinic visits between 14 surgeons (6 otolaryngologists and 8 endocrine surgeons) and 49 patients with low‐risk (cT1‐2, N0) thyroid cancer were audio‐recorded and transcribed. Qualitative analysis was used to evaluate surgeon counseling strategies and patient concerns related to voice.Results: Patients aged from 20 to 77 years old were predominantly female (77.6%) and white (89.9%). Surgeons presented risk with negative framing and numerical percentages (1%‐4%) and/or qualified the risk as “low” or “small” for a lobectomy, but a “much bigger deal” for bilateral nerve injury in total thyroidectomy. At a minimum, surgeons referred to voice dysfunction as “voice change.” Some further described “hoarseness” or the “inability to project voice.” Other surgeons imitated what voice dysfunction would sound like. A few surgeons probed the importance of voice to a patient's life. One surgeon imparted that having a voice‐related complication “can be really emotional.” Patients responded with varying degrees of concern about voice changes after surgery, from feeling “super concerned … about losing [their] voice” to feeling “ok” with it “as long as [they're] around to deal with it.”Conclusion: Significant variability exists in how surgeons describe and set expectations about voice‐related complications. The degree to which patients value voice‐related outcomes differed based on their occupation and hobbies, but this was tempered by their cancer diagnosis. Further research is needed to identify optimal disclosure of voice‐related risks and expectations.
- Open Access
- 3 February 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (7) , 8063-8072
Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations
Background: Data on the clinical value of second opinions in oncology are limited. We examined diagnostic and treatment changes resulting from second opinions and the expected impact on morbidity and prognosis.Methods: This retrospective cohort study included patients presenting in 2018 to a high‐volume cancer center for second opinions about newly diagnosed colorectal, head and neck, lung, and myeloma cancers or abnormal results. Two sub‐specialty physicians from each cancer type reviewed 30 medical records (120 total) using a process and detailed data collection guide meant to mitigate institutional bias. The primary outcome measure was the rate of treatment changes that were “clinically meaningful”, i.e., expected to impact morbidity and/or prognosis. Among those with treatment changes, another outcome measure was the rate of clinically meaningful diagnostic changes that led to treatment change.Results: Of 120 cases, forty‐two had clinically meaningful changes in treatment with positive expected outcomes (7 colorectal, 17 head and neck, 11 lung, 7 myeloma; 23–57%). Two patients had negative expected outcomes from having sought a second opinion, with worse short‐term morbidity and unchanged long‐term morbidity and prognosis. All those with positive expected outcomes had improved expected morbidity (short‐ and/or long‐term); 11 (0–23%) also had improved expected prognosis. Nine involved a shift from treatment to observation; 21 involved eliminating or reducing the extent of surgery, compared to 6 adding surgery or increasing its extent. Of the 42 with treatment changes, 13 were due to clinically meaningful diagnostic changes (1 colorectal, 5 head and neck, 3 lung, 4 myeloma; 3%–17%) .Conclusions: Second‐opinion consultations sometimes add clinical value by improving expected prognoses; more often, they offer treatment de‐escalations, with corresponding reductions in expected short‐ and/or long‐term morbidity. Future research could identify subgroups of patients most likely to benefit from second opinions.
- 3 February 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (7) , 8063-8072
Open AccessClinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations
Background: Data on the clinical value of second opinions in oncology are limited. We examined diagnostic and treatment changes resulting from second opinions and the expected impact on morbidity and prognosis.Methods: This retrospective cohort study included patients presenting in 2018 to a high‐volume cancer center for second opinions about newly diagnosed colorectal, head and neck, lung, and myeloma cancers or abnormal results. Two sub‐specialty physicians from each cancer type reviewed 30 medical records (120 total) using a process and detailed data collection guide meant to mitigate institutional bias. The primary outcome measure was the rate of treatment changes that were “clinically meaningful”, i.e., expected to impact morbidity and/or prognosis. Among those with treatment changes, another outcome measure was the rate of clinically meaningful diagnostic changes that led to treatment change.Results: Of 120 cases, forty‐two had clinically meaningful changes in treatment with positive expected outcomes (7 colorectal, 17 head and neck, 11 lung, 7 myeloma; 23–57%). Two patients had negative expected outcomes from having sought a second opinion, with worse short‐term morbidity and unchanged long‐term morbidity and prognosis. All those with positive expected outcomes had improved expected morbidity (short‐ and/or long‐term); 11 (0–23%) also had improved expected prognosis. Nine involved a shift from treatment to observation; 21 involved eliminating or reducing the extent of surgery, compared to 6 adding surgery or increasing its extent. Of the 42 with treatment changes, 13 were due to clinically meaningful diagnostic changes (1 colorectal, 5 head and neck, 3 lung, 4 myeloma; 3%–17%) .Conclusions: Second‐opinion consultations sometimes add clinical value by improving expected prognoses; more often, they offer treatment de‐escalations, with corresponding reductions in expected short‐ and/or long‐term morbidity. Future research could identify subgroups of patients most likely to benefit from second opinions.
- Top Cited Papers
- 23 September 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 124 (6) , 920-922
Epidemiology and incidence of HPV‐related cancers of the head and neck
Globally, 4.5% of cancers are due to the human papillomavirus (HPV). In the United States, 80 million people are infected with HPV, and the incidence of HPV oropharyngeal cancer has surpassed HPV cervical cancer. The highest burden of oropharyngeal cancer is seen in middle‐aged and increasingly older White men. HPV vaccination promises to change the epidemiology of this disease, but HPV vaccination rates remain too low today to reduce disease transmission.
- 23 September 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 124 (6) , 920-922
Top Cited PapersEpidemiology and incidence of HPV‐related cancers of the head and neck
Globally, 4.5% of cancers are due to the human papillomavirus (HPV). In the United States, 80 million people are infected with HPV, and the incidence of HPV oropharyngeal cancer has surpassed HPV cervical cancer. The highest burden of oropharyngeal cancer is seen in middle‐aged and increasingly older White men. HPV vaccination promises to change the epidemiology of this disease, but HPV vaccination rates remain too low today to reduce disease transmission.
- 14 August 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 124 (8) , 1272-1283
Travel distance is associated with stage at presentation and laryngectomy rates among patients with laryngeal cancer
Background: The impact of travel distance on stage at presentation and management strategies of laryngeal squamous cell carcinoma (SCC) is unknown. We investigated this relationship.Methods: Retrospective review of patients with laryngeal SCC in the National Cancer Data Base from 2004 to 2016. Multivariate analysis determined relationships between travel distance, sociodemographic, geographic, and hospital factors. Logistic regression determined the influence of travel distance on T‐stage and overall stage at presentation, and receipt of total laryngectomy.Results: Sixty thousand four hundred and thirty‐nine patients were divided into groups based on distance to treatment: short (50 miles). Increased travel was associated with T4‐stage (intermediate vs. short OR 1.11, CI 1.04–1.18, p = 0.001; long vs. short OR 1.5, CI 1.36–1.65, p < 0.001), and total laryngectomy (intermediate vs. short OR 1.40, CI 1.3–1.5, p ≤ 0.001; long vs. short OR 2.52, CI 2.28–2.79, p ≤ 0.001). In T4 disease, total laryngectomy was associated with improved survival compared to nonsurgical treatment (HR 0.75, CI 0.70–0.80, p < 0.001) regardless of travel distance.Conclusion: Longer travel distance to care is associated with increased stage at presentation, rate of laryngectomy, and improved survival in advanced laryngeal SCC. Health policy efforts should be directed towards improving early access to diagnosis and care.
- 14 August 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 124 (8) , 1272-1283
Travel distance is associated with stage at presentation and laryngectomy rates among patients with laryngeal cancer
Background: The impact of travel distance on stage at presentation and management strategies of laryngeal squamous cell carcinoma (SCC) is unknown. We investigated this relationship.Methods: Retrospective review of patients with laryngeal SCC in the National Cancer Data Base from 2004 to 2016. Multivariate analysis determined relationships between travel distance, sociodemographic, geographic, and hospital factors. Logistic regression determined the influence of travel distance on T‐stage and overall stage at presentation, and receipt of total laryngectomy.Results: Sixty thousand four hundred and thirty‐nine patients were divided into groups based on distance to treatment: short (50 miles). Increased travel was associated with T4‐stage (intermediate vs. short OR 1.11, CI 1.04–1.18, p = 0.001; long vs. short OR 1.5, CI 1.36–1.65, p < 0.001), and total laryngectomy (intermediate vs. short OR 1.40, CI 1.3–1.5, p ≤ 0.001; long vs. short OR 2.52, CI 2.28–2.79, p ≤ 0.001). In T4 disease, total laryngectomy was associated with improved survival compared to nonsurgical treatment (HR 0.75, CI 0.70–0.80, p < 0.001) regardless of travel distance.Conclusion: Longer travel distance to care is associated with increased stage at presentation, rate of laryngectomy, and improved survival in advanced laryngeal SCC. Health policy efforts should be directed towards improving early access to diagnosis and care.
- 13 April 2021
- Published by Wiley in Head & Neck
- Vol. 43 (7) , 2110-2123
Disparities and guideline adherence for HPV testing among patients with oropharyngeal squamous cell carcinoma, NCDB, and SEER
Background: Human papilloma virus testing for oropharyngeal squamous‐cell carcinoma has been recommended by the National Comprehensive Cancer Network since 2012. We examine disparities, reported rates of human papillomavirus (HPV) testing, and the impact on these findings of limitations with the variable in database registries.Methods: The HPV variable was queried for patients with oropharyngeal squamous carcinoma (OPSCC) from 2013 to 2016 in National Cancer Data Base (NCDB) and Surveillance, Epidemiology, and End Results (SEER). Multivariable regression was used to identify disparities based on sociodemographic variables. Sensitivity analyses were used to investigate limitations of the variable.Results: Despite limitations in the HPV variable in the databases, there was less than 100% adherence to recommended testing, and there were significant disparities in multiple sociodemographic variables. For example, in NCDB 70% of white versus 60.4% of black patients were tested (odds ratio [OR] 0.75, confidence interval [CI] 0.66–0.85, p ≤ 0.0001); in SEER 59.8% of white and 47.6% of black patients were tested (OR 0.73, CI 0.67–0.81; p ≤ 0.0001).Conclusions: Disparities exist among patients undergoing testing for HPV‐associated OPSCC and adherence to guideline recommended HPV testing has been suboptimal. In addition, the HPV variable definition, especially as it relates to p16 positivity, and use in these two registries should be improved.
- 13 April 2021
- Published by Wiley in Head & Neck
- Vol. 43 (7) , 2110-2123
Disparities and guideline adherence for HPV testing among patients with oropharyngeal squamous cell carcinoma, NCDB, and SEER
Background: Human papilloma virus testing for oropharyngeal squamous‐cell carcinoma has been recommended by the National Comprehensive Cancer Network since 2012. We examine disparities, reported rates of human papillomavirus (HPV) testing, and the impact on these findings of limitations with the variable in database registries.Methods: The HPV variable was queried for patients with oropharyngeal squamous carcinoma (OPSCC) from 2013 to 2016 in National Cancer Data Base (NCDB) and Surveillance, Epidemiology, and End Results (SEER). Multivariable regression was used to identify disparities based on sociodemographic variables. Sensitivity analyses were used to investigate limitations of the variable.Results: Despite limitations in the HPV variable in the databases, there was less than 100% adherence to recommended testing, and there were significant disparities in multiple sociodemographic variables. For example, in NCDB 70% of white versus 60.4% of black patients were tested (odds ratio [OR] 0.75, confidence interval [CI] 0.66–0.85, p ≤ 0.0001); in SEER 59.8% of white and 47.6% of black patients were tested (OR 0.73, CI 0.67–0.81; p ≤ 0.0001).Conclusions: Disparities exist among patients undergoing testing for HPV‐associated OPSCC and adherence to guideline recommended HPV testing has been suboptimal. In addition, the HPV variable definition, especially as it relates to p16 positivity, and use in these two registries should be improved.
- 14 December 2020
- Published by Elsevier in Endocrine Practice
- Vol. 27 (3) , 228-235
Life Expectancy and Treatment Patterns in Elderly Patients With Low-Risk Papillary Thyroid Cancer: A Population-Based Analysis
- 14 December 2020
- Published by Elsevier in Endocrine Practice
- Vol. 27 (3) , 228-235
Life Expectancy and Treatment Patterns in Elderly Patients With Low-Risk Papillary Thyroid Cancer: A Population-Based Analysis